<DOC>
	<DOCNO>NCT00107419</DOCNO>
	<brief_summary>RATIONALE : Pemetrexed disodium may stop growth tumor cell block enzymes need cell growth . PURPOSE : This phase II trial study well pemetrexed disodium work treat patient recurrent unresectable metastatic chondrosarcoma .</brief_summary>
	<brief_title>S0423 Pemetrexed Disodium Treating Patients With Recurrent Unresectable Metastatic Chondrosarcoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine response rate ( confirm unconfirmed complete response partial response ) patient recurrent unresectable metastatic chondrosarcoma treat pemetrexed disodium . Secondary - Determine toxicity drug patient . - Correlate , preliminarily , response rate deletion methylthioadenosine phosphorylase ( MTAP ) , analyzed fluorescence in-situ hybridization ( FISH ) , patient treat drug . OUTLINE : This multicenter study . Patients stratify accord prior chemotherapy ( yes v ) . Patients receive pemetrexed disodium IV 10 minute day 1 . Courses repeat every 21 days* absence disease progression unacceptable toxicity . Beginning 7 day first dose pemetrexed disodium continue 21 day completion pemetrexed disodium , patient receive cyanocobalamin ( vitamin B_12 ) intramuscularly every 63 day oral folic acid daily . NOTE : *The duration course 1 28 day ; duration subsequent course 21 day . Patients achieve complete response ( CR ) receive 2 additional course beyond CR . Patients achieve confirm partial response ( PR ) resectable , proceed surgical resection receive 2 additional course therapy recover surgery . Patients achieve confirmed PR resectable continue treatment absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month disease progression every 6 month 5 year . PROJECTED ACCRUAL : A total 40-75 patient ( 20-40 previously treat stratum 20-35 previously untreated stratum ) accrue study within 20-37.5 month .</detailed_description>
	<mesh_term>Chondrosarcoma</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm chondrosarcoma Histologic grade G2 G3 Recurrent unresectable OR metastatic disease Measurable disease xray , scan , ultrasound , physical examination No know CNS metastases PATIENT CHARACTERISTICS : Age 18 Performance status Zubrod 02 Life expectancy Not specify Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic Bilirubin &lt; 1.5 time upper limit normal ( ULN ) SGOT SGPT &lt; 2.5 time ULN ( 5 time ULN liver metastasis present ) Renal Creatinine clearance &gt; 45 mL/min Other Not pregnant nursing Fertile patient must use effective contraception Able swallow oral medication No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer , carcinoma situ cervix , adequately treated stage I II cancer complete remission PRIOR CONCURRENT THERAPY : Biologic therapy More 28 day since prior biologic therapy malignancy Chemotherapy More 28 day since prior chemotherapy malignancy Endocrine therapy Not specify Radiotherapy At least 60 day since prior radiotherapy target lesion* No concurrent radiotherapy NOTE : *Target lesion must demonstrate disease progression completion therapy Surgery At least 21 day since prior surgery recover Other More 28 day since prior investigational drug malignancy At least 60 day since prior embolization radiofrequency ablation target lesion* No 2 prior treatment regimen malignancy No concurrent antiretroviral therapy HIVpositive patient NOTE : *Target lesion must demonstrate disease progression completion therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>chondrosarcoma</keyword>
</DOC>